193 related articles for article (PubMed ID: 29066719)
1. Gene isoforms as expression-based biomarkers predictive of drug response in vitro.
Safikhani Z; Smirnov P; Thu KL; Silvester J; El-Hachem N; Quevedo R; Lupien M; Mak TW; Cescon D; Haibe-Kains B
Nat Commun; 2017 Oct; 8(1):1126. PubMed ID: 29066719
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide DNA copy number predictors of lapatinib sensitivity in tumor-derived cell lines.
Greshock J; Cheng J; Rusnak D; Martin AM; Wooster R; Gilmer T; Lee K; Weber BL; Zaks T
Mol Cancer Ther; 2008 Apr; 7(4):935-43. PubMed ID: 18413807
[TBL] [Abstract][Full Text] [Related]
3. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
Spoerke JM; O'Brien C; Huw L; Koeppen H; Fridlyand J; Brachmann RK; Haverty PM; Pandita A; Mohan S; Sampath D; Friedman LS; Ross L; Hampton GM; Amler LC; Shames DS; Lackner MR
Clin Cancer Res; 2012 Dec; 18(24):6771-83. PubMed ID: 23136191
[TBL] [Abstract][Full Text] [Related]
4. Genome-Scale Signatures of Gene Interaction from Compound Screens Predict Clinical Efficacy of Targeted Cancer Therapies.
Jiang P; Lee W; Li X; Johnson C; Liu JS; Brown M; Aster JC; Liu XS
Cell Syst; 2018 Mar; 6(3):343-354.e5. PubMed ID: 29428415
[TBL] [Abstract][Full Text] [Related]
5. Network-based approach to identify principal isoforms among four cancer types.
Ma J; Wang J; Ghoraie LS; Men X; Haibe-Kains B; Dai P
Mol Omics; 2019 Apr; 15(2):117-129. PubMed ID: 30720033
[TBL] [Abstract][Full Text] [Related]
6. Leukocyte common antigen-related tyrosine phosphatase receptor: increased expression and neuronal-type splicing in breast cancer cells and tissue.
Yang T; Zhang JS; Massa SM; Han X; Longo FM
Mol Carcinog; 1999 Jun; 25(2):139-49. PubMed ID: 10365916
[TBL] [Abstract][Full Text] [Related]
7. Discovering long noncoding RNA predictors of anticancer drug sensitivity beyond protein-coding genes.
Nath A; Lau EYT; Lee AM; Geeleher P; Cho WCS; Huang RS
Proc Natl Acad Sci U S A; 2019 Oct; 116(44):22020-22029. PubMed ID: 31548386
[TBL] [Abstract][Full Text] [Related]
8. A method for identifying discriminative isoform-specific peptides for clinical proteomics application.
Zhang F; Chen JY
BMC Genomics; 2016 Aug; 17 Suppl 7(Suppl 7):522. PubMed ID: 27557076
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive expression-based isoform biomarkers predictive of drug responses based on isoform co-expression networks and clinical data.
Ma J; Wang J; Ghoraie LS; Men X; Chen R; Dai P
Genomics; 2020 Jan; 112(1):647-658. PubMed ID: 31029864
[TBL] [Abstract][Full Text] [Related]
10. [Polygenetic pharmacogenomic strategies to identify drug sensitivity biomarkers].
Nishiyama M
Gan To Kagaku Ryoho; 2005 Nov; 32(12):1902-7. PubMed ID: 16282724
[TBL] [Abstract][Full Text] [Related]
11. Cell-Line Selectivity Improves the Predictive Power of Pharmacogenomic Analyses and Helps Identify NADPH as Biomarker for Ferroptosis Sensitivity.
Shimada K; Hayano M; Pagano NC; Stockwell BR
Cell Chem Biol; 2016 Feb; 23(2):225-235. PubMed ID: 26853626
[TBL] [Abstract][Full Text] [Related]
12. Transcript Profiling Using Long-Read Sequencing Technologies.
Bayega A; Wang YC; Oikonomopoulos S; Djambazian H; Fahiminiya S; Ragoussis J
Methods Mol Biol; 2018; 1783():121-147. PubMed ID: 29767360
[TBL] [Abstract][Full Text] [Related]
13. Alternative Splicing in Adhesion- and Motility-Related Genes in Breast Cancer.
Aversa R; Sorrentino A; Esposito R; Ambrosio MR; Amato A; Zambelli A; Ciccodicola A; D'Apice L; Costa V
Int J Mol Sci; 2016 Jan; 17(1):. PubMed ID: 26784191
[TBL] [Abstract][Full Text] [Related]
14. Development of a Drug-Response Modeling Framework to Identify Cell Line Derived Translational Biomarkers That Can Predict Treatment Outcome to Erlotinib or Sorafenib.
Li B; Shin H; Gulbekyan G; Pustovalova O; Nikolsky Y; Hope A; Bessarabova M; Schu M; Kolpakova-Hart E; Merberg D; Dorner A; Trepicchio WL
PLoS One; 2015; 10(6):e0130700. PubMed ID: 26107615
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia-dependent mRNA expression pattern of splicing factor YT521 and its impact on oncological important target gene expression.
Hirschfeld M; Zhang B; Jaeger M; Stamm S; Erbes T; Mayer S; Tong X; Stickeler E
Mol Carcinog; 2014 Nov; 53(11):883-92. PubMed ID: 23765422
[TBL] [Abstract][Full Text] [Related]
16. From General Aberrant Alternative Splicing in Cancers and Its Therapeutic Application to the Discovery of an Oncogenic DMTF1 Isoform.
Tian N; Li J; Shi J; Sui G
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28257090
[TBL] [Abstract][Full Text] [Related]
17. Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy.
Shee K; Wells JD; Jiang A; Miller TW
PLoS One; 2019; 14(11):e0224267. PubMed ID: 31682620
[TBL] [Abstract][Full Text] [Related]
18. The expression signature of cancer-associated KRAB-ZNF factors identified in TCGA pan-cancer transcriptomic data.
Machnik M; Cylwa R; Kiełczewski K; Biecek P; Liloglou T; Mackiewicz A; Oleksiewicz U
Mol Oncol; 2019 Apr; 13(4):701-724. PubMed ID: 30444046
[TBL] [Abstract][Full Text] [Related]
19. Bimodal Gene Expression in Patients with Cancer Provides Interpretable Biomarkers for Drug Sensitivity.
Ba-Alawi W; Nair SK; Li B; Mammoliti A; Smirnov P; Mer AS; Penn LZ; Haibe-Kains B
Cancer Res; 2022 Jul; 82(13):2378-2387. PubMed ID: 35536872
[TBL] [Abstract][Full Text] [Related]
20. Molecular assay to generate expression profile of eight estrogen receptor alpha isoform mRNA copy numbers in picogram amounts of total RNA from breast cancer tissues.
Poola I
Anal Biochem; 2003 Mar; 314(2):217-26. PubMed ID: 12654308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
